Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Renegotiations During Trigger Fix Could Endanger Program – Schultz

This article was originally published in The Gray Sheet

Executive Summary

CDRH is crediting the device user fee program with bringing greater visibility and leverage to the device sector and is urging cooperation to ensure the program does not lapse at the end of fiscal 2005

You may also be interested in...



MDUFMA Reauthorization Will Be AdvaMed’s Forum For Revisiting Goals

AdvaMed's proposed legislative changes to the Medical Device User Fee & Modernization Act now include a plea to forgive $4 mil. on behalf of industry

MDUFMA Reauthorization Will Be AdvaMed’s Forum For Revisiting Goals

AdvaMed's proposed legislative changes to the Medical Device User Fee & Modernization Act now include a plea to forgive $4 mil. on behalf of industry

Senate Aide Advises FDA Dialogue, Not Legislation, To Obtain User Fee Relief

Manufacturers seeking to revise CDRH performance goals and user fee collection targets are unlikely to find a suitable vehicle in MDUFMA "trigger-fix" legislation this fall

Related Content

UsernamePublicRestriction

Register

MT021224

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel